JOHNSON & JOHNSON (1JNJ.MI) Stock Fundamental Analysis

BIT:1JNJ • US4781601046

206.35 EUR
+0.3 (+0.15%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Taking everything into account, 1JNJ scores 5 out of 10 in our fundamental rating. 1JNJ was compared to 52 industry peers in the Pharmaceuticals industry. 1JNJ has an excellent profitability rating, but there are some minor concerns on its financial health. 1JNJ is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year 1JNJ was profitable.
  • 1JNJ had a positive operating cash flow in the past year.
  • 1JNJ had positive earnings in each of the past 5 years.
  • 1JNJ had a positive operating cash flow in 4 of the past 5 years.
1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCF1JNJ.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • 1JNJ has a Return On Assets of 13.03%. This is amongst the best in the industry. 1JNJ outperforms 86.54% of its industry peers.
  • 1JNJ's Return On Equity of 31.69% is fine compared to the rest of the industry. 1JNJ outperforms 76.92% of its industry peers.
  • 1JNJ has a Return On Invested Capital of 14.16%. This is in the better half of the industry: 1JNJ outperforms 69.23% of its industry peers.
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROIC 14.16%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1JNJ.MI Yearly ROA, ROE, ROIC1JNJ.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • 1JNJ's Profit Margin of 27.26% is amongst the best of the industry. 1JNJ outperforms 88.46% of its industry peers.
  • In the last couple of years the Profit Margin of 1JNJ has grown nicely.
  • 1JNJ has a Operating Margin of 27.00%. This is in the better half of the industry: 1JNJ outperforms 69.23% of its industry peers.
  • 1JNJ's Operating Margin has improved in the last couple of years.
  • The Gross Margin of 1JNJ (68.14%) is comparable to the rest of the industry.
  • 1JNJ's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27%
PM (TTM) 27.26%
GM 68.14%
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
1JNJ.MI Yearly Profit, Operating, Gross Margins1JNJ.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • 1JNJ has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • There is no outstanding debt for 1JNJ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
1JNJ.MI Yearly Shares Outstanding1JNJ.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
1JNJ.MI Yearly Total Debt VS Total Assets1JNJ.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • An Altman-Z score of 5.23 indicates that 1JNJ is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of 1JNJ (5.23) is better than 75.00% of its industry peers.
  • 1JNJ has a debt to FCF ratio of 2.34. This is a good value and a sign of high solvency as 1JNJ would need 2.34 years to pay back of all of its debts.
  • 1JNJ has a better Debt to FCF ratio (2.34) than 84.62% of its industry peers.
  • 1JNJ has a Debt/Equity ratio of 0.55. This is a neutral value indicating 1JNJ is somewhat dependend on debt financing.
  • 1JNJ has a Debt to Equity ratio of 0.55. This is in the better half of the industry: 1JNJ outperforms 61.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Altman-Z 5.23
ROIC/WACC1.47
WACC9.6%
1JNJ.MI Yearly LT Debt VS Equity VS FCF1JNJ.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.3 Liquidity

  • 1JNJ has a Current Ratio of 1.07. This is a normal value and indicates that 1JNJ is financially healthy and should not expect problems in meeting its short term obligations.
  • 1JNJ's Current ratio of 1.07 is on the low side compared to the rest of the industry. 1JNJ is outperformed by 71.15% of its industry peers.
  • 1JNJ has a Quick Ratio of 1.07. This is a bad value and indicates that 1JNJ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 1JNJ has a Quick ratio of 0.80. This is in the lower half of the industry: 1JNJ underperforms 65.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 0.8
1JNJ.MI Yearly Current Assets VS Current Liabilites1JNJ.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • 1JNJ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.11%, which is quite good.
  • 1JNJ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.11% yearly.
  • The Revenue has been growing slightly by 6.05% in the past year.
  • The Revenue has been growing slightly by 2.67% on average over the past years.
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.75% on average over the next years. This is quite good.
  • Based on estimates for the next years, 1JNJ will show a small growth in Revenue. The Revenue will grow by 6.02% on average per year.
EPS Next Y7.88%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
EPS Next 5Y8.75%
Revenue Next Year7.21%
Revenue Next 2Y6.4%
Revenue Next 3Y6.15%
Revenue Next 5Y6.02%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
1JNJ.MI Yearly Revenue VS Estimates1JNJ.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
1JNJ.MI Yearly EPS VS Estimates1JNJ.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • 1JNJ is valuated rather expensively with a Price/Earnings ratio of 22.45.
  • 1JNJ's Price/Earnings ratio is in line with the industry average.
  • 1JNJ's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.99.
  • A Price/Forward Earnings ratio of 20.82 indicates a rather expensive valuation of 1JNJ.
  • The rest of the industry has a similar Price/Forward Earnings ratio as 1JNJ.
  • When comparing the Price/Forward Earnings ratio of 1JNJ to the average of the S&P500 Index (28.06), we can say 1JNJ is valued slightly cheaper.
Industry RankSector Rank
PE 22.45
Fwd PE 20.82
1JNJ.MI Price Earnings VS Forward Price Earnings1JNJ.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 1JNJ's Enterprise Value to EBITDA ratio is in line with the industry average.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as 1JNJ.
Industry RankSector Rank
P/FCF 29.82
EV/EBITDA 18.5
1JNJ.MI Per share data1JNJ.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • 1JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.85
PEG (5Y)3.68
EPS Next 2Y8.2%
EPS Next 3Y8.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 2.13%, 1JNJ has a reasonable but not impressive dividend return.
  • 1JNJ's Dividend Yield is comparable with the industry average which is at 1.91.
  • Compared to an average S&P500 Dividend Yield of 1.81, 1JNJ has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.13%

5.2 History

  • On average, the dividend of 1JNJ grows each year by 9.24%, which is quite nice.
Dividend Growth(5Y)9.24%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 1JNJ pays out 48.70% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of 1JNJ is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP48.7%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
1JNJ.MI Yearly Income VS Free CF VS Dividend1JNJ.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
1JNJ.MI Dividend Payout.1JNJ.MI Dividend Payout, showing the Payout Ratio.1JNJ.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

JOHNSON & JOHNSON

BIT:1JNJ (2/18/2026, 7:00:00 PM)

206.35

+0.3 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-21
Earnings (Next)04-14
Inst Owners75.09%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap497.16B
Revenue(TTM)94.19B
Net Income(TTM)25.12B
Analysts75.63
Price Target197.26 (-4.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.13%
Yearly Dividend4.14
Dividend Growth(5Y)9.24%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.42%
Min EPS beat(2)0.55%
Max EPS beat(2)2.3%
EPS beat(4)4
Avg EPS beat(4)2.37%
Min EPS beat(4)0.55%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.79%
EPS beat(12)11
Avg EPS beat(12)3.6%
EPS beat(16)14
Avg EPS beat(16)3.08%
Revenue beat(2)2
Avg Revenue beat(2)1.48%
Min Revenue beat(2)0.03%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)0.74%
Min Revenue beat(4)-0.55%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.34%
Revenue beat(12)7
Avg Revenue beat(12)-2.01%
Revenue beat(16)7
Avg Revenue beat(16)-8.34%
PT rev (1m)7.4%
PT rev (3m)11.85%
EPS NQ rev (1m)0.04%
EPS NQ rev (3m)-3.62%
EPS NY rev (1m)0.79%
EPS NY rev (3m)-0.01%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)1.63%
Revenue NY rev (3m)1.84%
Valuation
Industry RankSector Rank
PE 22.45
Fwd PE 20.82
P/S 6.34
P/FCF 29.82
P/OCF 24.14
P/B 7.37
P/tB N/A
EV/EBITDA 18.5
EPS(TTM)9.19
EY4.45%
EPS(NY)9.91
Fwd EY4.8%
FCF(TTM)6.92
FCFY3.35%
OCF(TTM)8.55
OCFY4.14%
SpS32.54
BVpS28
TBVpS-6.18
PEG (NY)2.85
PEG (5Y)3.68
Graham Number76.09
Profitability
Industry RankSector Rank
ROA 13.03%
ROE 31.69%
ROCE 17.53%
ROIC 14.16%
ROICexc 16.21%
ROICexgc 66.83%
OM 27%
PM (TTM) 27.26%
GM 68.14%
FCFM 21.27%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y6.15%
OM growth 5Y6.99%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.67%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 2.34
Debt/EBITDA 1.36
Cap/Depr 62.36%
Cap/Sales 5%
Interest Coverage 250
Cash Conversion 75.02%
Profit Quality 78.02%
Current Ratio 1.07
Quick Ratio 0.8
Altman-Z 5.23
F-Score4
WACC9.6%
ROIC/WACC1.47
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.11%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%20.59%
EPS Next Y7.88%
EPS Next 2Y8.2%
EPS Next 3Y8.39%
EPS Next 5Y8.75%
Revenue 1Y (TTM)6.05%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.08%
Revenue Next Year7.21%
Revenue Next 2Y6.4%
Revenue Next 3Y6.15%
Revenue Next 5Y6.02%
EBIT growth 1Y2.89%
EBIT growth 3Y12.1%
EBIT growth 5Y9.84%
EBIT Next Year23.35%
EBIT Next 3Y11.24%
EBIT Next 5Y8.55%
FCF growth 1Y-5.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.75%
OCF growth 3YN/A
OCF growth 5YN/A

JOHNSON & JOHNSON / 1JNJ.MI FAQ

What is the fundamental rating for 1JNJ stock?

ChartMill assigns a fundamental rating of 5 / 10 to 1JNJ.MI.


What is the valuation status of JOHNSON & JOHNSON (1JNJ.MI) stock?

ChartMill assigns a valuation rating of 3 / 10 to JOHNSON & JOHNSON (1JNJ.MI). This can be considered as Overvalued.


Can you provide the profitability details for JOHNSON & JOHNSON?

JOHNSON & JOHNSON (1JNJ.MI) has a profitability rating of 7 / 10.


What is the valuation of JOHNSON & JOHNSON based on its PE and PB ratios?

The Price/Earnings (PE) ratio for JOHNSON & JOHNSON (1JNJ.MI) is 22.45 and the Price/Book (PB) ratio is 7.37.


What is the financial health of JOHNSON & JOHNSON (1JNJ.MI) stock?

The financial health rating of JOHNSON & JOHNSON (1JNJ.MI) is 5 / 10.